-
2
-
-
0033971102
-
Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
-
(2000)
Vaccine
, vol.18
, pp. 1456-1466
-
-
De Kleijn, E.D.1
De Groot, R.2
Labadie, J.3
Lafeber, A.B.4
Van den Dobbelsteen, G.5
Van Alphen, L.6
Van Dijken, H.7
Kuipers, B.8
Van Omme, G.W.9
Wala, M.10
Juttmann, R.11
Rumke, H.C.12
-
4
-
-
0001835786
-
Meningococcal vaccines: Past, present and future
-
K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons, New York, N.Y.
-
(1995)
, pp. 245-283
-
-
Frasch, C.E.1
-
13
-
-
0034616767
-
Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial
-
(2000)
JAMA
, vol.283
, pp. 2795-2801
-
-
MacLennan, J.M.1
Shackley, F.2
Heath, P.T.3
Deeks, J.J.4
Flamank, C.5
Herbert, M.6
Griffiths, H.7
Hatzmann, E.8
Goilav, C.9
Moxon, E.R.10
-
14
-
-
0028883439
-
Complement-mediated bactericidal activity of human antibodies to poly alpha 2→8 N-acetyl-neuraminic acid, the capsular polysaccharide of Neisseria meningitidis sero-group B
-
(1995)
J. Infect. Dis.
, vol.172
, pp. 1279-1289
-
-
Mandrell, R.E.1
Azmi, F.H.2
Granoff, D.M.3
-
15
-
-
0342891343
-
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays
-
(1997)
Clin. Diagn. Lab. Immunol.
, vol.4
, pp. 156-167
-
-
Maslanka, S.E.1
Gheesling, L.L.2
Libutti, D.E.3
Donaldson, K.B.4
Harakeh, H.S.5
Dykes, J.K.6
Arhin, F.F.7
Devi, S.J.8
Frasch, C.E.9
Huang, J.C.10
Kriz-Kuzemenska, P.11
Lemmon, R.D.12
Lorange, M.13
Peeters, C.C.14
Quataert, S.15
Tai, J.Y.16
Carlone, G.M.17
-
16
-
-
0031813368
-
Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine
-
(1998)
Infect. Immun.
, vol.66
, pp. 2453-2459
-
-
Maslanka, S.E.1
Tappero, J.W.2
Plikaytis, B.D.3
Brumberg, R.S.4
Dykes, J.K.5
Gheesling, L.L.6
Donaldson, K.B.7
Schuchat, A.8
Pullman, J.9
Jones, M.10
Bushmaker, J.11
Carlone, G.M.12
-
17
-
-
0030197579
-
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
-
(1996)
Vaccine
, vol.14
, pp. 1009-1015
-
-
Peeters, C.C.1
Rumke, H.C.2
Sundermann, L.C.3
Rouppe Van der Voort, E.M.4
Meulenbelt, J.5
Schuller, M.6
Kuipers, A.J.7
Van der Ley, P.8
Poolman, J.T.9
-
18
-
-
0033611936
-
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
-
(1999)
JAMA
, vol.281
, pp. 1520-1527
-
-
Tappero, J.W.1
Lagos, R.2
Ballesteros, A.M.3
Plikaytis, B.4
Williams, D.5
Dykes, J.6
Gheesling, L.L.7
Carlone, G.M.8
Hoiby, E.A.9
Holst, J.10
Nokdeby, H.11
Rosenqvist, E.12
Sierra, G.13
Campa, C.14
Sotolongo, F.15
Vega, J.16
Garcia, J.17
Herrera, P.18
Poolman, J.T.19
Perkins, B.A.20
more..
-
19
-
-
0017682906
-
Standardization and control of meningococcal vaccines, group A and group C polysaccharides
-
(1977)
J. Biol. Stand.
, vol.5
, pp. 197-215
-
-
Wong, K.H.1
Barrera, O.2
Sutton, A.3
May, J.4
Hochstein, D.H.5
Robbins, J.D.6
Robbins, J.B.7
Parkman, P.D.E.8
Eligmann B.S., Jr.9
-
20
-
-
0003473977
-
Requirements for meningococcal polysaccharide vaccine (requirements for biological substances no. 23)
-
(1976)
WHO Tech. Rep. Ser.
, vol.594
, pp. 72-73
-
-
-
21
-
-
0020665394
-
Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide
-
(1983)
Infect. Immun.
, vol.40
, pp. 257-264
-
-
Zollinger, W.D.1
Mandrell, R.E.2
|